![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: MMP11 |
Gene summary for MMP11 |
![]() |
Gene information | Species | Human | Gene symbol | MMP11 | Gene ID | 4320 |
Gene name | matrix metallopeptidase 11 | |
Gene Alias | SL-3 | |
Cytomap | 22q11.23 | |
Gene Type | protein-coding | GO ID | GO:0006508 | UniProtAcc | B3KQS8 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
4320 | MMP11 | AEH-subject1 | Human | Endometrium | AEH | 1.24e-37 | -1.02e+00 | -0.3059 |
4320 | MMP11 | AEH-subject2 | Human | Endometrium | AEH | 1.25e-30 | -9.66e-01 | -0.2525 |
4320 | MMP11 | AEH-subject3 | Human | Endometrium | AEH | 4.91e-21 | -8.01e-01 | -0.2576 |
4320 | MMP11 | AEH-subject4 | Human | Endometrium | AEH | 7.37e-03 | -4.24e-01 | -0.2657 |
4320 | MMP11 | AEH-subject5 | Human | Endometrium | AEH | 8.52e-63 | -1.23e+00 | -0.2953 |
4320 | MMP11 | EEC-subject1 | Human | Endometrium | EEC | 9.72e-52 | -1.16e+00 | -0.2682 |
4320 | MMP11 | EEC-subject2 | Human | Endometrium | EEC | 9.32e-53 | -1.15e+00 | -0.2607 |
4320 | MMP11 | EEC-subject3 | Human | Endometrium | EEC | 5.24e-56 | -1.13e+00 | -0.2525 |
4320 | MMP11 | EEC-subject4 | Human | Endometrium | EEC | 2.88e-52 | -1.14e+00 | -0.2571 |
4320 | MMP11 | EEC-subject5 | Human | Endometrium | EEC | 1.22e-40 | -1.04e+00 | -0.249 |
4320 | MMP11 | GSM5276934 | Human | Endometrium | EEC | 7.00e-47 | -1.09e+00 | -0.0913 |
4320 | MMP11 | GSM5276935 | Human | Endometrium | EEC | 1.31e-38 | -1.03e+00 | -0.123 |
4320 | MMP11 | GSM5276937 | Human | Endometrium | EEC | 1.10e-29 | -1.00e+00 | -0.0897 |
4320 | MMP11 | GSM6177620_NYU_UCEC1_lib1_lib1 | Human | Endometrium | EEC | 2.31e-49 | -1.23e+00 | -0.1869 |
4320 | MMP11 | GSM6177620_NYU_UCEC1_lib2_lib2 | Human | Endometrium | EEC | 1.92e-44 | -1.21e+00 | -0.1875 |
4320 | MMP11 | GSM6177620_NYU_UCEC1_lib3_lib3 | Human | Endometrium | EEC | 1.86e-54 | -1.24e+00 | -0.1883 |
4320 | MMP11 | GSM6177621_NYU_UCEC2_lib1_lib1 | Human | Endometrium | EEC | 5.49e-52 | -1.12e+00 | -0.1934 |
4320 | MMP11 | GSM6177622_NYU_UCEC3_lib1_lib1 | Human | Endometrium | EEC | 1.97e-49 | -1.10e+00 | -0.1917 |
4320 | MMP11 | GSM6177622_NYU_UCEC3_lib2_lib2 | Human | Endometrium | EEC | 7.88e-65 | -1.23e+00 | -0.1916 |
4320 | MMP11 | LZE21D1 | Human | Esophagus | HGIN | 1.54e-02 | 3.23e-01 | 0.0632 |
Page: 1 2 3 4 5 |
![]() |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | ![]() |
Colorectum | SER | ![]() |
Colorectum | MSS | ![]() |
Colorectum | MSI-H | ![]() |
Colorectum | FAP | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:00454448 | Oral cavity | OSCC | fat cell differentiation | 120/7305 | 229/18723 | 2.48e-05 | 2.32e-04 | 120 |
GO:00455983 | Oral cavity | OSCC | regulation of fat cell differentiation | 77/7305 | 139/18723 | 6.36e-05 | 5.18e-04 | 77 |
GO:00301983 | Oral cavity | OSCC | extracellular matrix organization | 146/7305 | 301/18723 | 4.67e-04 | 2.77e-03 | 146 |
GO:00452293 | Oral cavity | OSCC | external encapsulating structure organization | 147/7305 | 304/18723 | 5.30e-04 | 3.08e-03 | 147 |
GO:00430623 | Oral cavity | OSCC | extracellular structure organization | 146/7305 | 302/18723 | 5.59e-04 | 3.23e-03 | 146 |
GO:00226171 | Oral cavity | OSCC | extracellular matrix disassembly | 37/7305 | 63/18723 | 1.18e-03 | 5.99e-03 | 37 |
GO:00717114 | Oral cavity | OSCC | basement membrane organization | 20/7305 | 31/18723 | 3.57e-03 | 1.49e-02 | 20 |
GO:0032963 | Oral cavity | OSCC | collagen metabolic process | 54/7305 | 104/18723 | 5.00e-03 | 1.96e-02 | 54 |
GO:0022411110 | Oral cavity | LP | cellular component disassembly | 173/4623 | 443/18723 | 9.97e-12 | 7.44e-10 | 173 |
Page: 1 2 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
MMP11 | SNV | Missense_Mutation | c.1323G>C | p.Gln441His | p.Q441H | P24347 | protein_coding | tolerated(0.08) | probably_damaging(0.954) | TCGA-AN-A0FL-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
MMP11 | SNV | Missense_Mutation | rs767579900 | c.1186G>A | p.Glu396Lys | p.E396K | P24347 | protein_coding | tolerated(0.15) | benign(0.265) | TCGA-EW-A1PH-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cyclophosphamide | SD |
MMP11 | insertion | Nonsense_Mutation | novel | c.1037_1038insTTGACCCCTACCACAGA | p.Phe347Ter | p.F347* | P24347 | protein_coding | TCGA-A8-A09K-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | ||
MMP11 | SNV | Missense_Mutation | rs879000719 | c.1001N>A | p.Arg334His | p.R334H | P24347 | protein_coding | tolerated(0.09) | benign(0.284) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
MMP11 | SNV | Missense_Mutation | rs750098875 | c.1123N>A | p.Ala375Thr | p.A375T | P24347 | protein_coding | tolerated(0.63) | benign(0.049) | TCGA-EA-A3HU-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
MMP11 | SNV | Missense_Mutation | novel | c.1246N>T | p.Arg416Trp | p.R416W | P24347 | protein_coding | deleterious(0) | probably_damaging(0.91) | TCGA-VS-A9U6-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | PD |
MMP11 | SNV | Missense_Mutation | c.839A>G | p.Asn280Ser | p.N280S | P24347 | protein_coding | tolerated(0.11) | benign(0.125) | TCGA-AA-3672-01 | Colorectum | colon adenocarcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD | |
MMP11 | SNV | Missense_Mutation | rs143231653 | c.478G>A | p.Ala160Thr | p.A160T | P24347 | protein_coding | tolerated(1) | benign(0.003) | TCGA-AA-3864-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
MMP11 | SNV | Missense_Mutation | c.1348C>A | p.Leu450Met | p.L450M | P24347 | protein_coding | deleterious(0.01) | probably_damaging(0.988) | TCGA-AA-A01R-01 | Colorectum | colon adenocarcinoma | Male | <65 | III/IV | Chemotherapy | 5-fluorouracil | PD | |
MMP11 | SNV | Missense_Mutation | rs563846943 | c.310C>T | p.Arg104Cys | p.R104C | P24347 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-CM-4751-01 | Colorectum | colon adenocarcinoma | Male | <65 | III/IV | Chemotherapy | oxaliplatin | SD |
Page: 1 2 3 4 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
4320 | MMP11 | PROTEASE, DRUGGABLE GENOME, ENZYME | inhibitor | 252166865 |
Page: 1 |